Home / Events / Company News / What is minimal residual disease (MRD)?
What is minimal residual disease (MRD)?
Jan. 18 2023

Minimal Residual Disease (MRD) was initially proposed in blood disorders, which refers to the presence of trace amounts of malignant tumor cells in the body during the disease remission (CR) after clinical treatment. These cells may cause the relapse of hematological malignancies.

 

An MRD test looks for any cancer cells that were not killed by chemotherapy or other cancer treatments. MRD is a measure used for multiple myeloma, lymphoma, leukemia, and other blood cancers.

 

MEDx HemeMRD kit is used to quantitatively (relatively quantitatively) detect the rearrangement of human B lymphocyte antigen receptor (BCR) gene. For patients with acute B lymphoblastic leukemia (B-ALL), multiple myeloma (MM), and chronic lymphoblastic leukemia (CLL), the CDR3 sequence of BCR gene is amplified by multiplex PCR and analyzed by NGS during the initial diagnosis to screen out the dominant tumor clonal sequences. During the treatment, the patient samples were regularly monitored for the load level of clonal sequences to assist drug efficacy evaluation, relapse monitoring, and clone evolution tracking.


Advantages of HEME-MRD Detection

o     High sensitivity: Sensitivity as high as 0.0001%

o     Broad applicationss: Suitable for B-ALL, MM and CLL patients

o   Detection of new clones: Identifications of clone evolutions, immune recovery, and immune reconstitution

o     Excellent repeatability: Standardarized  experimental process and bioinformatics analysis


Indications of HEME-MRD Detection

Applicable disease type

Specimen type

Acute B lymphoblastic leukemia (B-ALL)

Bone marrow or peripheral blood

Multiple myeloma (MM)

Bone marrow or peripheral blood

Chronic lymphocytic leukemia (CLL)

Bone marrow or peripheral blood

 

Sample Requirementsand Sensitivity 


Specimen

Volume

Shipping conditions


Specimen

 Volume

Shipping conditions


Sensitivity

DNA Amount (ug)

Before treatment

Bone marrow (fresh)

1mL

4 ℃48h


After treatment

Bone marrow (fresh)

2-3mL

4, 48h


10-4

2ug

Peripheral blood (fresh)

2-3mL

4 ℃48h

Peripheral blood (fresh)

>5mL

4, 48h


10-5

7ug

DNA

2ug

Dry ice , 48h

DNA

>7ug

Dry ice, 48h


10-6

20ug


If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.


1. Customized or bulk orders of IVD/CDx products.

2. Get a quote for IVD/CDx products

3. Become our distributor

4. Get customized pharmaceutical service solutions

5.Learn more about our technology and R&D


Show of MEDx by CCTV